CIC
TCRT icon

Carnegie Investment Counsel’s Alaunos Therapeutics TCRT Stock Holding History

Carnegie Investment Counsel’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-67
Closed -$116K – 301
2015
Q1 		$116K Buy
+67
New +$99.3K 0.02% 295

Other funds holding TCRT

UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carnegie Investment Counsel's TCRT Position: Q2 2015 in Review

Carnegie Investment Counsel sold out of Alaunos Therapeutics (TCRT) in Q2 2015, closing a stake of 67 shares — an estimated $116K sold.

Carnegie Investment Counsel first reported a position in TCRT in Q1 2015 and held it in 1 quarter. The position peaked at $116K in Q1 2015. 156 funds tracked by Wall St. Rank hold TCRT as of Q2 2015.

  • Carnegie Investment Counsel reported no remaining Alaunos Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Carnegie Investment Counsel sold 67 Alaunos Therapeutics shares in Q2 2015, an estimated $116K.
  • Carnegie Investment Counsel first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 1 quarter.
  • Carnegie Investment Counsel's Alaunos Therapeutics position peaked at $116K in Q1 2015.
  • 156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2015.

Based on Carnegie Investment Counsel's 13F filing for Q2 2015, filed 13 Aug 2015.